"Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) are standard treatments for EGFR-mutated non-small cell lung cancer (NSCLC).
• Therapeutic resistance to EGFR TKIs is inevitable, leading to treatment failure.
• Numerous uncommon EGFR mutations are insensitive to current EGFR TKIs, highlighting a critical unmet clinical need.

Purpose of the Study:

• To critically review the combination strategy of EGFR TKIs and monoclonal antibodies (mAbs) for treating uncommon EGFR mutation-positive NSCLC.
• To discuss the preclinical data, clinical implications, limitations, and future prospects of this combination therapy.

Main Methods:

• Review of preclinical studies investigating the efficacy of combined EGFR TKI and mAb regimens.
• Analysis of clinical trial data and case reports on combination therapy for uncommon EGFR mutations.
• Evaluation of the mechanisms of action and resistance pathways targeted by the combination strategy.

Main Results:

• Combination therapy demonstrates potential in overcoming resistance mechanisms and targeting uncommon EGFR mutations.
• Preclinical and early clinical data suggest enhanced EGFR inhibition at cellular, animal, and human levels.
• The combination strategy may offer a more intensive inhibition compared to single-agent therapies.

Conclusions:

• Combination therapy of EGFR TKIs and mAbs represents a viable strategy for managing uncommon EGFR mutation-positive NSCLC.
• Further clinical investigation is warranted to establish the safety, efficacy, and optimal use of this combination regimen.
• Addressing resistance and uncommon mutations is crucial for improving long-term outcomes in EGFR-mutated NSCLC.